These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 7530585

  • 1. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL, Hall D, Hattox SE, Spector SA, Stein DS, Myers M.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb 01; 8(2):141-51. PubMed ID: 7530585
    [Abstract] [Full Text] [Related]

  • 2. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb 01; 10 Suppl 1():S57. PubMed ID: 8595510
    [Abstract] [Full Text] [Related]

  • 3. Nevirapine triple combo results released.
    Common Factor; 1995 Apr 01; (no 10):21. PubMed ID: 11362346
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S, Lazzarin A, Carosi G, Sinicco A, Armignacco O, Angarano G, Andreoni M, Tambussi G, Chiodera A, Floridia M, Scaccabarozzi S, Facey K, Duncan I, Boudes P, Bragman K.
    Antivir Ther; 1996 Aug 01; 1(3):129-40. PubMed ID: 11322246
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
    de Jong MD, Loewenthal M, Boucher CA, van der Ende I, Hall D, Schipper P, Imrie A, Weigel HM, Kauffmann RH, Koster R.
    J Infect Dis; 1994 Jun 01; 169(6):1346-50. PubMed ID: 8195615
    [Abstract] [Full Text] [Related]

  • 8. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study.
    Meng TC, Fischl MA, Cheeseman SH, Spector SA, Resnick L, Boota A, Petrakis T, Wright B, Richman DD.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb 01; 8(2):152-60. PubMed ID: 7834398
    [Abstract] [Full Text] [Related]

  • 9. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J.
    Antivir Ther; 2002 Jun 01; 7(2):81-90. PubMed ID: 12212928
    [Abstract] [Full Text] [Related]

  • 10. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, Timpone J, Myers M, Basgoz N, Niu M, Hirsch MS.
    Ann Intern Med; 1996 Jun 15; 124(12):1019-30. PubMed ID: 8633815
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. New combo trial/same old style.
    Gilden D.
    GMHC Treat Issues; 1995 Apr 15; 9(4):9. PubMed ID: 11362369
    [Abstract] [Full Text] [Related]

  • 13. Nevirapine surprise.
    Smart T.
    GMHC Treat Issues; 1996 Apr 15; 10(6/7):25. PubMed ID: 11363640
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.
    Thistle P, Spitzer RF, Glazier RH, Pilon R, Arbess G, Simor A, Boyle E, Chitsike I, Chipato T, Gottesman M, Silverman M.
    Clin Infect Dis; 2007 Jan 01; 44(1):111-9. PubMed ID: 17143826
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
    Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D.
    J Virol; 1994 Mar 01; 68(3):1660-6. PubMed ID: 7509000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.